Publicacións nas que colabora con Rafael Bárcena Marugán (21)

2016

  1. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

2012

  1. Safe coadministration of raltegravir-based HAART in HIV-infected patients with HCV-cirrhosis receiving triple therapy with telaprevir or boceprevir.

    Journal of acquired immune deficiency syndromes (1999)

2011

  1. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia

    Liver Transplantation, Vol. 17, Núm. 3, pp. 331-333

2010

  1. Raltegravir-based highly active antiretroviral therapy has beneficial effects on the renal function of human immunodeficiency virus-infected patients after solid organ transplantation

    Liver Transplantation

  2. Safe co-administration of raltegravir, pegylated-interferon and, ribavirin in HIV individuals with hepatitis C virus-related liver damage

    AIDS

2009

  1. False-positive results of aspergillus galactomannan antigenemia in liver transplant recipients

    Transplantation, Vol. 87, Núm. 2, pp. 256-260

2008

  1. Safe use of raltegravir and sirolimus in an HIV-infected patient with renal impairment after orthotopic liver transplantation

    AIDS

  2. Severe Sirolimus-Related Inflammatory State Anemia in an HIV+ Liver Transplant Patient With Calcineurin Inhibitor Renal Insufficiency: A Case Report

    Transplantation Proceedings, Vol. 40, Núm. 10, pp. 3810-3812

2007

  1. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1

    Antiviral Therapy, Vol. 12, Núm. 3, pp. 401-406

2006

  1. Syncytial giant cell hepatitis in human immunodeficiency virus-infected patients with chronic hepatitis C: 2 cases and review of the literature

    Human Pathology, Vol. 37, Núm. 10, pp. 1344-1349

  2. Viral kinetics and early prediction of nonresponse to peg-IFN-α-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus

    Journal of Viral Hepatitis, Vol. 13, Núm. 7, pp. 466-473

2005

  1. Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: An intent to find the optimal cut-off value

    Journal of Clinical Virology, Vol. 33, Núm. 2, pp. 138-144

  2. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-α-2b/ribavirin

    Journal of Hepatology, Vol. 43, Núm. 5, pp. 783-790

  3. Liver transplantation in HIV-infected recipients

    Liver Transplantation, Vol. 11, Núm. 1, pp. 76-81

  4. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization

    European Journal of Gastroenterology and Hepatology, Vol. 17, Núm. 11, pp. 1157-1164

2004

  1. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin

    Antiviral Therapy, Vol. 9, Núm. 1, pp. 133-138

  2. Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin

    Antiviral Therapy, Vol. 9, Núm. 6, pp. 1027-1030

  3. Pegylated interferon α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

    AIDS, Vol. 18, Núm. 1, pp. 67-73

2003

  1. Prevention of invasive fungal infections in liver transplant recipients: The role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 813-819

2002

  1. Prophylaxis with oral fluconazole and an oral solution of amphotericin B in liver transplant patients

    Transplantation Proceedings, Vol. 34, Núm. 1, pp. 80-81